Flexion Therapeutics Inc. (NASDAQ:FLXN) Latest News, Stock Price and Trading Information

Flexion Therapeutics Presents New Data Evaluating Repeat Administration of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in Patients with Advanced Knee OA

Globe Newswire 15-Jul 7:30 AM

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire 3-Jul 4:30 PM

Flexion Therapeutics Named one of Boston Business Journal's Best Places to Work for the Third Consecutive Year

Globe Newswire 20-Jun 9:01 AM

Flexion Therapeutics to Present at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference

Globe Newswire 18-Jun 4:30 PM

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire 7-Jun 4:30 PM

Flexion Therapeutics Announces Issuance of New U.S. Patent Covering FX201 a Gene Therapy Product Candidate for the Treatment of Osteoarthritis

Globe Newswire 5-Jun 8:31 AM

Scientist.com Partners With 5AM Ventures to Create an R&D Marketplace for Biotech Startups

Business Wire 29-May 7:55 AM

Flexion Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference

Globe Newswire 14-May 4:30 PM

Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA (triamcinolone acetonide extended-release injectable suspension)

Globe Newswire 10-May 7:30 AM

Flexion Therapeutics Reports First-Quarter 2019 Financial Results and Recent Business Highlights

Globe Newswire 8-May 4:01 PM

Flexion Therapeutics, Inc. to Host Earnings Call

ACCESSWIRE 8-May 2:45 PM